latent GDF-8

latent GDF-8

latent GDF-8 Informations sur la molécule

Molecule Name
Growth/differentiation factor 8
Alias de la molécule
latent GDF-8
Drug Development Progress
Nombre de médicaments cliniques6
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéeNDA/BLA
Alias de la cible
MSTN,GDF-8,GDF8,Growth Differentiation Factor 8,MSLHP,Myostatin,Growth/Differentiation Factor 8
Contexte de la molécule
Growth differentiation factor 8 (GDF8), also known as myostatin, is a unique member of the transforming growth factor-β superfamily that is expressed in human granulosa cells and has important roles in regulating a variety of ovarian functions. GDF8 acts as a negative regulator of skeletal muscle growth and differentiation. In addition to the expression in the musculoskeletal system, GDF8 is also expressed in various tissues, including the reproductive system.

Demande de produit

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
Talditercept alfaRO-7239361; BMS-986089; RG-6206; BHV-2000Phase 3 ClinicalBristol-Myers Squibb Company
Muscular Dystrophy, Duchenne; Neuromuscular Diseases; Muscular Atrophy, Spinal
Details
RO-7204239GYM-329; RO-7204239; RG-6237; RG-70240Phase 3 ClinicalF. Hoffmann-La Roche Ltd, Chugai Pharmaceutical Co Ltd
Muscular Dystrophy, Facioscapulohumeral; Muscular Atrophy, Spinal
Details
TrevogrumabREGN-1033; REGN1033; SAR-391786; GDF8Phase 2 ClinicalRegeneron Pharmaceuticals Inc
Myositis, Inclusion Body; Obesity; Sarcopenia
Details
AAV1-FS344AAV1-Follistatin; AAV1-FS344Phase 2 ClinicalNationwide Children'S Hospital
Becker muscular dystrophy; Myositis, Inclusion Body; Muscular Dystrophy, Duchenne
Details
KER-065KER-065; RKER-065Phase 1 ClinicalKeros Therapeutics Inc
Neuromuscular Diseases; Obesity
Details
HS135HS-135Phase 1 Clinical35Pharma Inc
Hypertension, Pulmonary; Heart Failure, Diastolic; Pulmonary Arterial Hypertension
Details